Product · Materials Science
Product · InnDex 62 · Evidence provided · High specification risk
Graphene-platelet admixture reducing cement content in concrete while maintaining strength and lowering embodied carbon.
Concretene is a graphene-based admixture engineered to densify cement-paste microstructure, enabling 15–30% performance gains in concrete, grout and mortar. It addresses the embodied-carbon intensity of cement (8% of global CO₂) by allowing proportional cement reduction without sacrificing design strength. The product is cost-neutral at scale because savings from reduced cement offset the admixture cost.
Concretene introduces graphene platelets into the cementitious mix to densify paste microstructure, allowing cement content to be reduced while maintaining design strength — with the admixture cost claimed to offset cement savings at scale, making the embodied-carbon reduction theoretically cost-neutral. The field validation extends beyond lab claims: over 300 m³ across gym floors, railway sleepers, and precast piles with 18–22% measured strength uplift provides more deployment substance than most admixture products in this category. The honest qualification the record makes itself is worth emphasising: laboratory-claimed strength gains of 32.5% compress to 18–22% in real-world field conditions, a signal that the gap between controlled and site performance is meaningful and that conservative factor assumptions belong in structural specifications. Graphene dispersion and long-term durability in the concrete matrix — under chloride ingress, carbonation, and thermal cycling — are understudied beyond a four-year pilot window, and the cost-neutrality case depends on project scale; small volumes or regions with low cement costs will not achieve the equation. Batch-to-batch consistency of graphene platelets and their dispersion in production mixes is a quality-control overhead that standard concrete supply chains are not designed to manage. Warrants a closer look for high-volume concrete programmes where embodied carbon is tracked and the contractor can accommodate upstream supply integration; the diligence question is confirming regulatory acceptance in the jurisdiction and establishing QA protocols before committing at programme scale.
Funding (£378k + £1m Innovate UK) is verifiable and credible. Field trial existence (2021–2025 across named applications) is stated but not independently verified in accessible reports. Lab-to-field strength uplift variance (32.5% → 18–22%) is explained by real-world conditions but suggests sensitivity to placement and curing. No publicly accessible third-party certified EPD or whole-mix LCA found; carbon claims rest on the logic that cement-content reduction = proportional carbon saving, which ignores graphene production footprint, transport, and potential mix-design complexity. Cost-neutrality claim ('price of admixture = cost of cement removed') is plausible but not independently audited. Deployment scale (300 m³) is small relative to UK concrete market (~20M m³/year).
#graphene #embodied-carbon #concrete-admixture #cement-reduction #nanotechnology